Equities Analysts Set Expectations for Aclaris Therapeutics Inc’s Q1 2018 Earnings (ACRS)
Aclaris Therapeutics Inc (NASDAQ:ACRS) – Investment analysts at Leerink Swann issued their Q1 2018 EPS estimates for Aclaris Therapeutics in a research note issued on Monday. Leerink Swann analyst S. Fernandez forecasts that the biotechnology company will earn ($1.06) per share for the quarter. Leerink Swann has a “Outperform” rating and a $54.00 price target on the stock. Leerink Swann also issued estimates for Aclaris Therapeutics’ Q2 2018 earnings at ($0.84) EPS, Q3 2018 earnings at ($1.16) EPS and Q4 2018 earnings at ($1.29) EPS.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at $19.66 on Wednesday. Aclaris Therapeutics has a fifty-two week low of $18.46 and a fifty-two week high of $33.10. The stock has a market cap of $590.79 and a PE ratio of -7.96.
A number of hedge funds have recently added to or reduced their stakes in ACRS. Franklin Resources Inc. lifted its stake in shares of Aclaris Therapeutics by 27.9% in the fourth quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock valued at $64,037,000 after buying an additional 565,945 shares during the period. BlackRock Inc. lifted its stake in shares of Aclaris Therapeutics by 28.4% in the fourth quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock valued at $54,129,000 after buying an additional 485,146 shares during the period. AXA bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $6,455,000. Driehaus Capital Management LLC lifted its stake in shares of Aclaris Therapeutics by 73.8% in the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock valued at $12,908,000 after buying an additional 222,254 shares during the period. Finally, Alyeska Investment Group L.P. lifted its stake in shares of Aclaris Therapeutics by 85.2% in the third quarter. Alyeska Investment Group L.P. now owns 467,884 shares of the biotechnology company’s stock valued at $12,076,000 after buying an additional 215,201 shares during the period. Institutional investors own 92.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Set Expectations for Aclaris Therapeutics Inc’s Q1 2018 Earnings (ACRS)” was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/03/15/equities-analysts-set-expectations-for-aclaris-therapeutics-incs-q1-2018-earnings-acrs.html.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.